Table 1. Effects of MSCs derivatives on HSPCs and Hematopoiesis .
| MSCs derivatives | Effects on HSPCs and Hematopoiesis | References |
| SCF TPO CXCL12 flt3l PGE2 miR221, miR451, miR654-3p |
HSPCs expansion and development | 57,133 |
| IL-3, IL-6, IL-11 G-CSF |
HSPCs differentiation | 57 |
| TPO | Early Megakaryocyte differentiation | 95 |
| IL-11 | Platelet formation | 95 |
| IL-6 G-CSF |
Myeloid differentiation | 96,97 |
| IL-6 in combination with SCF Laminin miR-223 |
HSPCs proliferation | 96,97,122,134 |
| SCF/c-kit (CD117) | Myeloid and Erythroid differentiation | 98,99 |
| CXCL8, CXCL12, CXCL16 CCL2, CCL5 CX3CL1 (fractalkine) Flt-3 ligand(FL) SCF, G-CSF, VEGF VCAM-1, E-selectin Collagen I Fibronectin, Laminin, Vimentin miR-126 |
HSPC homing and mobilization | 124-128 |
| CXCL12 (SDF-1) | Early B-cell lymphopoiesis Preservation, Quiescence |
117,118,129-131 |
| VEGF FGF-2 Angiopoetin-1 (Ang-1) |
Homing and reduction apoptosis | 132 |
| IL-10 | Increased CD5+ regulatory B cells generation | 138 |
| IL-6 and M-CSF | Inhibit DCs differentiation | 139 |
| M-CSF, HGF IL-6, IL-10 TNF PGE2 TGF-β COX-1, COX-2 IDO or NO HLA-G5 |
Immunosuppressive and immunomodulation | 140,141,146 |
| IDO | M2 macrophage differentiation | 148 |
| miR-451 | Erythroid differentiation | 89 |
| CEBPA/miR-182 EGR2/miR-150 miR-92, miR-9, miR-150 MPO/ hsa_piR_020814_ DQ598650 |
Apoptosis and differentiation | 88,107,108 |
| hsa_piR_020814_DQ598650 | Regulates MPO synthesis during myeloid differentiation | 106 |
| miR210-5p miR106b-3p miR155-5p |
Inhibited radiation-induced apoptosis of HSPC | 133 |
| miR-21-5p miR-181a-5p miR92a-3p |
Reduction of caspase dependent apoptosis | 88 |